Want to see CARM full AI Analyst Report?
Ct-0525
Her2-Positive
Phase I
Active Not Recruiting
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
Feb 02, 2024
―
Pembrolizumab, Ct-0508
Prostate Cancer, Bladder Cancer, Ovarian Neoplasms, Colorectal Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Endometrial Cancer, Head And Neck Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Biliary Tract Cancer, Carcinoma, Squamous, Adenocarcinoma, Lung Cancer, Small Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Carcinoma, Transitional Cell, Breast Neoplasm, Carcinoma, Small Cell, Esophagogastric Junction Neoplasms, Her-2 Protein Overexpression, Her2-Positive, Bile Duct Cancer, Carcinoma, Ductal, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Inflammatory Breast Cancer, Malignant Neoplasms, Her2-Positive Solid Tumors, Her-2 Gene Amplification
Phase I
Active Not Recruiting
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Nov 23, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Carisma Therapeutics (CARM) have in its pipeline
CARM is currently developing the following drugs: Ct-0525, Pembrolizumab, Ct-0508. These drug candidates are in various stages of clinical development as the company works toward FDA approval.